Nectin-4 Targeting ADC Probe for PET Imaging in Solid Tumors

• Status: Not yet recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To study the normal physiological distribution of the probe 124I-EV in human body and its ability to detect overexpression of Nectin-4 in tumor lesions.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Cancer Hospital
• Treatments: Fluorodeoxyglucose F18

Criteria

Inclusion Criteria:

1. 18-75 years old, male or female;

2. Patients recommended by clinicians to undergo PET/CT examination for tumor diagnostic staging;

3. The subject patients could fully understand and voluntarily participate in the experiment, and signed the informed consent.

4. Normal heart function;

5. Good follow-up compliance;

6. presence of at least one measurable target lesion according to RECIST1.1 criteria

7. Women of childbearing age (15-49 years) must have a negative pregnancy test within 7 days before the start of the test; Fertile men and women must agree to use effective contraception to prevent pregnancy during the study period and for 3 months after the test.

Exclusion Criteria:

1. Serious abnormality of liver, kidney and blood;

2. Pregnant patients;

3. Pregnant and lactation women;

3) unable to lie flat for half an hour; 4) Refuse to join the clinical investigator; 5) Suffering from claustrophobia or other mental diseases; 6) Other conditions that researchers deem unsuitable for participating in the experiment.